Phastar nabs AstraZeneca, CRUK veteran as data science lead

Jennifer Bradford will lead Phastar's data science team. (Phastar)

U.S.-London CRO Phastar has hired Jennifer Bradford, Ph.D., to lead its data science group.

Phastar, like an increasing number of CROs, is looking to get the best out of clinical trials, and it sees artificial intelligence (AI) and machine learning (ML) as two of the best ways of doing this.

Bradford will now lead its team of AI and ML scientists in its relatively new data science group as the company hopes to cash in on the trendy analytics that could open up new opportunities in drug development.

Featured Webinar

From Concept to Market: Overcoming the Challenges of Manufacturing and Clinical Trials

In this webinar we will reveal the inner workings of the manufacturing and pharmacy department of a CRO/CDMO, so you understand the different regulatory and operational considerations faced by a clinical research pharmacy.

Learn how CRO/CDMOs successfully address operational and regulatory challenges for pharmaceutical and biotechnology clients; and how this can make the difference between study success or failure.

She comes to the biopharma services provider from a diverse background, working at AstraZeneca for nearly eight years and moving up to become its principle informatics scientist, working on advanced analytics for the U.K.-based Big Pharma.

After that stint, she moved to Cancer Research UK, the London-based cancer charity and research group, as senior clinical informatician at its Manchester Institute.

RELATED: CRO Phastar pens tech deal with newly bought out Medidata

“Jennifer brings a deep knowledge and breadth of experience to PHASTAR,” said Kevin Kane, CEO and founder of Phastar.

“The increasing complexity of clinical trial data can bring the most value when advanced techniques are applied that can identify data sources and associated analytics to answer key questions throughout the trial period. With the leadership that Jennifer brings to Phastar, the Data Science Group combined with other Phastar resources, can make a significant difference in the efficacy of clinical trials.”

Suggested Articles

Matching the right patients to the right trials is a key piece of the recruitment puzzle. In oncology, it can be life and death.

U.K.-based CRO Sygnature Discovery is buying up fellow native life science services provider XenoGesis in order to boost its preclinical offerings.

PRA Health is tapping Deep Lens and the Microsoft Azure platform in matchmaking cancer patients to the right trials to speed up recruitment.